Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.
Sanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology drug pipeline and creating the possibility of new combination therapies
